Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

AXSM

Live52w high -1.7%

Annual Quarterly

Core line items from AXSM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: AXSOME THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$224.85M	$191.20M	$638.50M	$442.50M	$271.50M
Operating Income	Not available	$-63.36M	$-166.76M	$-139.81M	$-93.70M
Net Income	Not available	$-64.54M	$-183.17M	$-154.62M	$-47.97M
EPS (Diluted)	$-0.83	$-1.26	$-3.68	$-3.13	$-2.18
Total Assets	Not available	$713.61M	$689.80M	$669.25M	$639.78M
Total Liabilities	Not available	$659.02M	$601.51M	$595.52M	$566.71M
Cash & Equivalents	Not available	$305.11M	$322.93M	$325.27M	$303.02M
Free Cash Flow OCF − CapEx	Not available	$-20.82M	$-93.89M	$-75.16M	$-76.15M
Shares Outstanding	Not available	51.42M	50.88M	50.31M	49.82M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from AXSM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -1.7%

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: AXSOME THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$224.85M	$191.20M	$638.50M	$442.50M	$271.50M
Operating Income	Not available	$-63.36M	$-166.76M	$-139.81M	$-93.70M
Net Income	Not available	$-64.54M	$-183.17M	$-154.62M	$-47.97M
EPS (Diluted)	$-0.83	$-1.26	$-3.68	$-3.13	$-2.18
Total Assets	Not available	$713.61M	$689.80M	$669.25M	$639.78M
Total Liabilities	Not available	$659.02M	$601.51M	$595.52M	$566.71M
Cash & Equivalents	Not available	$305.11M	$322.93M	$325.27M	$303.02M
Free Cash Flow OCF − CapEx	Not available	$-20.82M	$-93.89M	$-75.16M	$-76.15M
Shares Outstanding	Not available	51.42M	50.88M	50.31M	49.82M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.